Preparation and characterization of camptothecin powder micronized by a supercritical antisolvent (SAS) process

被引:63
作者
Zhao, Xiuhua [1 ]
Zu, Yuangang [1 ]
Li, Qingyong [1 ]
Wang, Meixiang [1 ]
Zu, Baishi [1 ]
Zhang, Xiaonan [1 ]
Jiang, Ru [1 ]
Zu, Chunlin [1 ]
机构
[1] NE Forest Univ, Minist Educ, Key Lab Forest Plant Ecol, Harbin 150040, Heilongjiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Camptothecin; Supercritical antisolvent; Micronization; Preparation; Characterization; Nanosuspension; IN-VITRO; NANOPARTICLES; PRECIPITATION; CANCER; BIOAVAILABILITY; CYTOTOXICITY; FORMULATION; STABILITY; DELIVERY; COMPLEX;
D O I
10.1016/j.supflu.2009.10.004
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Micronized camptothecin (CPT) is prepared with a supercritical antisolvent (SAS) apparatus using dimethyl sulfoxide (DMSO) as solvent and carbon dioxide as antisolvent. Four factors, namely CPT solution concentration and flow rate, precipitation temperature and pressure are optimized by a four-level orthogonal array design (OAD). By analysis of variance (ANOVA), only precipitation pressure has a significant effect on the MPS of micronized CPT. The optimum micronization conditions are determined as follows: CPT solution concentration 1.25 mg/ml, CPT solution flow rate 6.6 ml/min, precipitation temperature 35 degrees C and precipitation pressure 20 MPa. Under the optimum conditions, micronized CPT with a MPS of 0.25 +/- 0.020 mu m is obtained. The micronized CPT obtained was characterized by Scanning Electron Microscopy (SEM), Atomic Force Microscope (AFM), High performance liquid chromatography-mass spectrometry (LC-MS), Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), Differential scanning calorimeters (DSC) and Gas chromatography (GC) analyses. The results showed that the obtained CPT particles have lower crystallinity and SAS micronization process does not induce degradation of CPT. In addition, the residual DMSO is less than the ICH limit for class 3 solvents. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:412 / 419
页数:8
相关论文
共 27 条
[1]  
ANDREATTA AE, 2008, J SUPERCRIT FLUID, V44, P273
[2]   Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer [J].
Chattopadhyay, P ;
Gupta, RB .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 228 (1-2) :19-31
[3]   Potential of poly(amidoamine) dendrimers as drug carriers of camptothecin based on encapsulation studies [J].
Cheng, Yiyun ;
Li, Minghong ;
Xu, Tongwen .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (08) :1791-1795
[4]  
CHIU HY, 2007, J SUPERCRIT FLUID, V42, P60
[5]   Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro [J].
Clements, MK ;
Wasi, S ;
Daoud, SS .
ANTI-CANCER DRUGS, 1996, 7 (08) :851-857
[6]   Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion [J].
Cortesi, R ;
Esposito, E ;
Maietti, A ;
Menegatti, E ;
Nastruzzi, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 159 (01) :95-103
[7]   DNA TOPOISOMERASE-I TARGETED CHEMOTHERAPY OF HUMAN-COLON CANCER IN XENOGRAFTS [J].
GIOVANELLA, BC ;
STEHLIN, JS ;
WALL, ME ;
WANI, MC ;
NICHOLAS, AW ;
LIU, LF ;
SILBER, R ;
POTMESIL, M .
SCIENCE, 1989, 246 (4933) :1046-1048
[8]   ON THE MECHANISM OF TOPOISOMERASE-I INHIBITION BY CAMPTOTHECIN - EVIDENCE FOR BINDING TO AN ENZYME DNA COMPLEX [J].
HERTZBERG, RP ;
CARANFA, MJ ;
HECHT, SM .
BIOCHEMISTRY, 1989, 28 (11) :4629-4638
[9]  
Inoue K, 2003, ADV EXP MED BIOL, V519, P145
[10]   Preparation and characterization of simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process [J].
Jun, Seoung Wook ;
Kim, Min-Soo ;
Kim, Jeong-Soo ;
Park, Hee Jun ;
Lee, Sibeum ;
Woo, Jong-Soo ;
Hwang, Sung-Joo .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 66 (03) :413-421